Cure8 news brief
A new EC approval makes ustekinumab an approved treatment option for children and adolescents (≥40 kg) with moderate–severe Crohn’s disease, potentially expanding choices for patients who haven’t responded to other therapies.
Pediatric patients with moderate–severe Crohn’s disease, parents and caregivers, pediatric and adult gastroenterologists, and patients currently on or considering biologic therapy.
This approval extends an existing adult Crohn’s indication to younger patients meeting the weight threshold, offering another biologic option for children and adolescents with moderate to severe disease who have not responded to conventional or biologic therapies.
The article summarizes key trial results (early response by week 3; remission rates reported at weeks 8 and 44) and mentions supportive real-world safety and effectiveness data.
If you or your child are considering treatment changes, clinicians will use the full trial and regulatory documents to decide whether ustekinumab is appropriate based on individual history, prior therapies, and growth/weight considerations. Dosing, monitoring, and eligibility (including the 40 kg weight cutoff) should be discussed with a treating specialist.
This news reflects a regulatory approval (European Commission) rather than new practice guidance; local availability, reimbursement, and national prescribing rules may vary.
The approval is based on a phase 3 trial (UNITI-Jr) and supporting real‑world data (REALITI). This is a regulatory update extending an existing adult indication; it does not itself provide detailed clinical guidance. Treatment decisions will depend on individual clinical factors and national reimbursement/availability.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Regulatory approval means ustekinumab (Stelara) can now be prescribed in the EU for some children with moderate‑to‑severe Crohn’s disease who haven’t responded to other treatments. This expands treatment options for...
This video quickly outlines the range of medical treatments now available for Crohn’s disease, including newer approvals. Knowing drug classes and recent options can help patients and clinicians discuss treatment plans...
This EC approval means ustekinumab (Stelara) is now an authorised treatment option in the EU for certain children and adolescents with moderate–severe Crohn’s disease who have not responded to other treatments.
